FY2024 Earnings Forecast for Invivyd Issued By HC Wainwright

Invivyd, Inc. (NASDAQ:IVVD) – Investment analysts at HC Wainwright cut their FY2024 earnings per share (EPS) estimates for Invivyd in a research note issued on Tuesday, February 4th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($1.64) for the year, down from their prior forecast of ($1.63). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Invivyd’s current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Invivyd’s Q4 2024 earnings at ($0.36) EPS.

IVVD has been the topic of a number of other reports. Morgan Stanley reduced their price objective on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Invivyd in a research note on Monday. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $7.89.

Invivyd Trading Down 6.2 %

Shares of IVVD opened at $1.98 on Thursday. The company’s fifty day simple moving average is $0.55 and its 200-day simple moving average is $0.83. The company has a market cap of $236.85 million, a P/E ratio of -1.01 and a beta of 0.61. Invivyd has a twelve month low of $0.35 and a twelve month high of $5.10.

Hedge Funds Weigh In On Invivyd

A number of large investors have recently bought and sold shares of IVVD. Proficio Capital Partners LLC bought a new stake in Invivyd during the 3rd quarter valued at $27,000. State Street Corp boosted its position in Invivyd by 3.7% during the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after purchasing an additional 35,904 shares in the last quarter. Cubist Systematic Strategies LLC lifted its position in shares of Invivyd by 66.1% during the second quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after buying an additional 53,499 shares during the last quarter. Barclays PLC boosted its holdings in shares of Invivyd by 179.6% in the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after buying an additional 75,780 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new position in shares of Invivyd in the 2nd quarter worth approximately $421,000. Institutional investors own 70.36% of the company’s stock.

Insiders Place Their Bets

In other news, Director Terrance Mcguire sold 160,400 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $0.59, for a total value of $94,636.00. Following the completion of the sale, the director now owns 4,202,679 shares of the company’s stock, valued at approximately $2,479,580.61. This represents a 3.68 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 816,466 shares of company stock worth $423,214 in the last ninety days. 17.90% of the stock is owned by company insiders.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.